ADAR and cancer: ADAR1 deletion in lung cancer models shows sensitivity to the basal expression of ISGs and an active IFN response, with SCLC being particularly more responsive, and the presence of ADAR1 appears to be associated with resistance to ICI therapy in certain cancers [87] (Figure 2B).